Placebo response is one of the biggest threats to clinical data analysis– especially when left unchecked. In this blog, we review the top three risks trial scientists must address (and how to address them).
Each September, pain advocates and specialists raise awareness about issues facing the millions of people living with chronic pain. One of the most pressing? The lack of treatments available to alleviate suffering. In this blog, we look at three top challenges of getting new pain drugs to market—and offer a potential solution.
Tools4Patient presented data at the MDS Congress 2021 that predicted the placebo response in Parkinson’s disease (PD) in a multi-center, multi-national clinical study.
Clinical trials measure efficacy of experimental therapies by comparing outcomes in patients receiving therapeutic interventions (treatment response) with patients receiving placebo (placebo response).
A representative from Tools4Patient discusses how grasping the ties between the two can help in reducing the impact of the placebo response in trials.
Placebo response is a major source of noise in trial data analysis, muddying the results and making it more difficult to detect true treatment effect. We know that it’s a pressing problem for clinical trials that needs solving, but where does it come from in the first place? Patient psychology, expectations and baseline severity of the disease play a significant part of a patient’s placebo responsiveness.